A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
Phase 2
80
about 2.5 years
18+
1 site in CA
About this study
This trial is testing a new vaccine, GEO-CM04S1, to see if it helps prevent COVID-19 infections in people with chronic lymphocytic leukemia. It compares this vaccine to the current standard of care vaccine and looks at whether the new vaccine boosts immunity better in patients with CLL.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
- 2.Receive mRNA COVID-19 Vaccine
- 3.Undergo Biospecimen Collection
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
vaccine, Immunological Agents
injection
Secondary: Confirmed COVID-19 infection by PCR viral load, Incidence of AEs unacceptable toxicity (UT), Incidence of adverse events (AEs) moderate toxicity (MOD), Incidence of serious adverse events (SAEs), SARS-CoV-2-S and -N specific IFNgamma (Th1) and IL-4 (Th2) cytokine levels following stimulation with overlapping peptide libraries specific for SARS-CoV-2
diagnostic
Oncology, Infectious